Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term efficacy and safety of pasireotide. This study was an open-label, single-arm, open-ended extension study (primary efficacy and safety evaluated at month 6). Patients could enter the extension if they achieved biochemical control (GH B 2.5 lg/L and normal IGF-1) or showed clinically relevant improvements during the core study. Thirty of the 60 patients who received pasireotide (200–900 lg bid) in the core study entered the extension. At extension month 6, of the 26 evaluable patients, six were biochemically controlled, of whom five had achieved control during the core study. Normal IGF-1 was achieved by 13/26 patients and GH B 2.5 lg/L by 12/26 at month 6. Nine patients received pasireotide for C24 months in the extension; three who were biochemically controlled at month 24 had achieved control during the core study. Of 29 patients with MRI data, nine had significant (C20 %) tumor volume reduction during the core study; an additional eight had significant reduction during the extension. The most common adverse events were transient gastrointestinal disturbances; Clinical Trials Registration Number: NCT00171730. Electronic supplementary material The online version of this article (doi:10.1007/s11102-013-0478-0) contains supplementary material, which is available to authorized users. S. Petersenn (&) ENDOC Center for Endocrine Tumors, Altonaer Str. 59, 20357 Hamburg, Germany e-mail: stephan.petersenn@endoc-med.de A. J. Farrall Brain Research Imaging Centre, Western General Hospital, University of Edinburgh, Edinburgh, UK C. Block Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium S. Melmed Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA J. Schopohl Medizinische Klinik und Poliklinik IV, Campus Innenstadt, University of Munich, Munich, Germany P. Caron Service d’Endocrinologie, Maladies Métaboliques et Nutrition, Centre Hospitalier Universitaire Larrey, Toulouse, France R. Cuneo Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia D. Kleinberg Neuroendocrine Unit, New York University School of Medicine, New York, NY, USA A. Colao Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, Naples, Italy M. Ruffin G. Hughes Novartis Pharma AG, Basel, Switzerland K. Hermosillo Reséndiz K. Hu Novartis Pharmaceuticals, East Hanover, NJ, USA A. Barkan Pituitary and Neuroendocrine Center, University of Michigan, Ann Arbor, MI, USA 123 Pituitary (2014) 17:132–140 DOI 10.1007/s11102-013-0478-0